Moderna Expects 2023 COVID-19 Vaccine Sales Of $6B-$8B, Dependent On US Vaccination Rates
Portfolio Pulse from Benzinga Newsdesk
Moderna anticipates its COVID-19 vaccine sales to range between $6 billion and $8 billion in 2023, contingent on US vaccination rates.
August 04, 2023 | 12:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Moderna's projected 2023 vaccine sales could impact its stock positively if the US vaccination rates remain high.
Moderna's revenue is heavily dependent on its COVID-19 vaccine sales. If the US maintains high vaccination rates, this could lead to increased sales for Moderna, positively impacting its stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100